Showing results (241-250 of 512) with videos related to
Sort By:
Pageof 52
European Journal of Biochemistry|April 24, 1999
Human high-Km 5'-nucleotidase effects of overexpression of the cloned cDNA in cultured human cellsC Rampazzo, C Gazziola, P Ferraro, et al.Optics Express|March 16, 2012
An automatic method for assembling a large synthetic aperture digital hologramA Pelagotti, M Paturzo, M Locatelli, et al.Lab on a Chip|December 15, 2015
Forward electrohydrodynamic inkjet printing of optical microlenses on microfluidic devicesV Vespini, S Coppola, M Todino, et al.Rheumatology (Oxford, England)|October 18, 2024
Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trialArthur Kavanaugh, Laura C Coates, Philip J Mease, et al.Arthritis Care & Research|May 11, 2021
Risk of Hospitalization for Serious Infection After Initiation of Ustekinumab or Other Biologics in Patients With Psoriasis or Psoriatic ArthritisYinzhu Jin, Hemin Lee, Moa P Lee, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|July 24, 2025
Improvement and maintenance of clinical outcome assessments in atopic dermatitis with amlitelimabAndrew Blauvelt, Raj Chovatiya, Joseph F Merola, et al.Journal of Psoriasis and Psoriatic Arthritis|May 5, 2026
Safety of IL-17A Inhibitors in Patients With Moderate to Severe Psoriasis in a US Claims Data-Based Cohort StudyMaria C Schneeweiss, Joseph F Merola, Yinzhu Jin, et al.Dermatology and Therapy|July 14, 2021
Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 TrialsRichard B Warren, Alice B Gottlieb, Joseph F Merola, et al.Journal of Drugs in Dermatology : JDD|March 17, 2017
The International Dermatology Outcome Measures (IDEOM) Initiative: A Review and UpdateScott A Elman, Joseph F Merola, April W Armstrong, et al.The Journal of Dermatological Treatment|March 8, 2021
Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasisSteven R Feldman, Joseph F Merola, David M Pariser, et al.Pageof 52